ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Roma, Lazio

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Roma, Lazio, ITA:

Locations recently updated

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Roma, RM, Italy and 66 other locations

Locations recently updated

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Roma, Italy and 75 other locations

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO)

ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non...

Enrolling
Mature B-Cell Non-Hodgkin Lymphoma
Drug: Ifosfamide
Drug: Rituximab

Phase 1, Phase 2

Roche
Roche

Roma, Lazio, Italy and 23 other locations

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).As of October 2022, no furt...

Active, not recruiting
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Drug: Cyclophosphamide
Biological: Brexucabtagene Autoleucel (KTE-X19)

Phase 1, Phase 2

Gilead Sciences
Gilead Sciences

Rome, Italy and 29 other locations

AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL (SOUNDTRACK-B)

monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least tw...

Enrolling
B-cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Drug: AZD0486

Phase 2

AstraZeneca
AstraZeneca

Roma, Italy and 80 other locations

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies (ELM-2)

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).T...

Enrolling
B-cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Odronextamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Terni, Italy and 137 other locations

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma...

Enrolling
Non-hodgkin Lymphoma
Drug: Epcoritamab

Phase 1

Genmab
Genmab

Rome, Roma, Italy and 40 other locations

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma...

Active, not recruiting
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Drug: zanubrutinib
Drug: rituximab

Phase 3

BeiGene
BeiGene

Roma, Italy and 179 other locations

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with...

Enrolling
Small Lymphocytic Lymphoma
Lymphoma, Non-Hodgkin
Drug: BMF-219

Phase 1

Biomea Fusion

Roma, Italy and 40 other locations

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib,...

Active, not recruiting
B-Cell Malignancies
Drug: parsaclisib + itacitinib
Drug: parsaclisib + ruxolitinib

Phase 2

Incyte
Incyte

Roma, Italy and 104 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems